ResearchMibefradil (Ro 40m5967) blocks multiple types of voltage-gated calcium channels in cultured rat spinal motoneurones
References (35)
Ro 40–5967, a novel calcium channel antagonist, protects against ventricular fibrillation
Eur J Pharmacol
(1992)- et al.
International Study Group. Effects of the new calcium antagonist mibefradil (Ro 40–5967) on exercise duration in patients with chronic stable angina pectoris: a multicenter, placebo-controlled study. Ro 40–5967
Am Heart J
(1995) - et al.
Effects of a new calcium antagonist, mibefradil (Ro 40–5967), on silent ischemia in patients with stable chronic angina pectoris: a multicenter placebo-controlled study
J Am Coll Cardiol
(1996) - et al.
Embryonic rat motoneurons express a functional P-type voltage-dependent calcium channel
Int J Dev Neurosci
(1995) - et al.
Purification of embryonic rat motoneurons by panning on a monoclonal antibody to the low-affinity NGF receptor
J Neurosci Methods
(1992) - et al.
Development alters the expression of calcium currents in chick limb motoneurons
Neuron
(1989) - et al.
Ca2+ channels: diversity of form and function
Curr Opin Neurobiol
(1992) - et al.
The structurally novel Call channel blocker Ro 40–5967, which binds to the [3H]-desmethoxyverapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat hearts
Cardiovasc Drugs Ther
(1990) - et al.
Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40–5967). A new generation of calcium antagonists?
Hypertension
(1996) - et al.
The effects of mibefradil, a novel calcium channel antagonist, on ventricular arrhythmias induced by myocardial ischemia and programmed electrical stimulation
J Pharmacol Exp Ther
(1996)
Selective inhibition of T -type Ca2+ channels by Ro 40–5967
Circ Res
(1994)
The Ca(++) channel blocker Ro 40–5967 blocks differently T-type and L-type Ca++ channels
J Pharmacol Exp Ther
(1994)
In vitro pharmacologic profile of Ro 40–5967, a novel Ca2+ channel blocker with potent vasodilator but weak inotropic action
J Cardiovasc Pharmacol
(1989)
Effects of Ro 40–5967, a novel calcium antagonist, on myocardial function during ischemia induced by lowering coronary perfusion pressure in dogs: comparison with verapamil
J Cardiovasc Pharmacol
(1989)
Lack of negative inotropic effects of the new calcium antagonist Ro 40–5967 in patients with stable angina pectoris
J Cardiovasc Pharmacol
(1991)
Mechanism of the anti-ischemic effect of mibefradil, a selective T calcium channel blocker in dogs: comparison with amlodipine
J Cardiovasc Pharmacol
(1996)
Mibefradil prevents neointima formation after vascular injury in rats. Possible role of the blockade of the T-type voltage-operated calcium channel
Arterioscler Thromb Vasc Biol
(1995)
Cited by (0)
Copyright © 1997 Published by Elsevier Ltd.